Ensysce Biosciences submits Phase 2a protocol for CY200 to UK regulator

September 24, 2026 8:02 AM

Ensysce Biosciences, Inc. (NASDAQ: ENSC) has submitted a Phase 2a clinical study protocol for its drug candidate CY200 to the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found